Circulating tumor cells from a 4-dimensional lung cancer model are resistant to cisplatin

Monika Vishnoi, Dhruva K. Mishra, Michael J. Thrall, Jonathan M. Kurie, Min P. Kim

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

Objective To determine the effect of cisplatin on circulatory tumor cells (CTC) and tumor nodules in a four-dimensional (4D) lung cancer model. Methods CTCs from the 4D model seeded with H1299, A549, or H460 and respective cells that were grown under two-dimensional conditions in a Petri dish were treated with 50 μM cisplatin for 24 and 48 hours and cell viability was determined. The lung nodules in the 4D model were then treated with different continuous or intermittent doses of cisplatin and the nodule size, the number of CTCs, and the level of matrix metalloproteinase (MMP) were determined. Results Cisplatin led to a significant decrease in the viability of tumor cells grown under 2D conditions (P <.01) but not in CTCs from the 4D model after both 24 hours and 48 hours. Cisplatin led to regression of tumor nodules with both the continuous and intermittent treatments. Moreover, there was a significantly higher number of CTCs per tumor area (P <.05) and MMP-2 production per tumor area (P =.007) for all human lung cancer cell lines grown in the 4D model when treated with cisplatin. Conclusions The 4D lung cancer model allows for the isolation of CTCs that are resistant to cisplatin treatment. The model may allow us to better understand the biology of cisplatin resistance.

Original languageEnglish (US)
Pages (from-to)1056-1064
Number of pages9
JournalJournal of Thoracic and Cardiovascular Surgery
Volume148
Issue number3
DOIs
StatePublished - Sep 2014

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Circulating tumor cells from a 4-dimensional lung cancer model are resistant to cisplatin'. Together they form a unique fingerprint.

Cite this